Chemomab Therapeutics Ltd.
CMMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534248
In the last 90 days, Chemomab Therapeutics Ltd. insiders filed 0 open-market purchases and 1 sale; 13 institutions reported holding it in 13F filings for Q2 2026, worth $615.3K in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Chemomab Therapeutics Ltd. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 10
- −4 vs. Q2 2025
- Shares held
- 390.3K
- −667.4K (−63.1%) vs. Q2 2025Converted for a 1-for-4 split
- Total value
- $1.03M
- −$3.88M (−79.1%) vs. Q2 2025
- New holders
- 1
- 2 more added
- Sold out
- 5
- 5 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CMMB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 13 | $615.3K |
| Q1 2026 | 15 | $551.9K |
| Q4 2025 | 14 | $606.1K |
| Q3 2025 | 10 | $1.03M |
| Q2 2025 | 14 | $4.91M |
| Q1 2025 | 17 | $4.07M |
| Q4 2024 | 16 | $7.53M |
| Q3 2024 | 15 | $7.14M |
| Q2 2024 | 15 | $2.44M |
| Q1 2024 | 14 | $2.07M |
| Q4 2023 | 16 | $1.43M |
| Q3 2023 | 11 | $2.26M |
| Q2 2023 | 11 | $3.33M |
| Q1 2023 | 13 | $4.56M |
| Q4 2022 | 14 | $10.6M |
| Q3 2022 | 15 | $8.09M |
| Q2 2022 | 13 | $12.2M |
| Q1 2022 | 15 | $15.9M |
| Q4 2021 | 14 | $22.7M |
| Q3 2021 | 15 | $35.9M |
| Q2 2021 | 12 | $58.7M |
| Q1 2021 | 10 | $82.6M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Chemomab Therapeutics Ltd.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sphera Funds Management Ltd. | 179,425 | $471.9K | 0.11% | −5,087−2.8% | ReducedConverted for a 1-for-4 split |
| Morgan Stanley | 90,065 | $236.9K | 0.00% | −313,469−77.7% | ReducedConverted for a 1-for-4 split |
| Ikarian Capital, LLC | 53,262 | $140.1K | 0.03% | 00.0% | UnchangedConverted for a 1-for-4 split |
| Stonepine Capital Management, LLC | 30,000 | $78.9K | 0.06% | +30,000 | New |
| Jane Street Group, LLC | 21,511 | $56.6K | 0.00% | +16,369+318.3% | AddedConverted for a 1-for-4 split |
| Rhumbline Advisers | 9,505 | $25.0K | 0.00% | −464−4.7% | ReducedConverted for a 1-for-4 split |
| BNP Paribas Arbitrage, SA | 5,750 | $15.1K | 0.00% | +2,275+65.5% | AddedConverted for a 1-for-4 split |
| GAMMA Investing LLC | 667 | $1.75K | 0.00% | −2,536−79.2% | ReducedConverted for a 1-for-4 split |
| UBS Group AG | 99 | $260 | 0.00% | 00.0% | UnchangedConverted for a 1-for-4 split |
| SBI Securities Co., Ltd. | 26 | $68 | 0.00% | −2−6.3% | ReducedConverted for a 1-for-4 split |
| OrbiMed Advisors LLC | 0 | $0 | 0.00% | −235,248−100.0% | Sold outConverted for a 1-for-4 split |
| Yelin Lapidot Holdings Management Ltd. | 0 | $0 | 0.00% | −144,573−100.0% | Sold outConverted for a 1-for-4 split |
| Kestra Private Wealth Services, LLC | 0 | $0 | 0.00% | −7,810−100.0% | Sold outConverted for a 1-for-4 split |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −6,547−100.0% | Sold outConverted for a 1-for-4 split |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −295−100.0% | Sold outConverted for a 1-for-4 split |